Prostamax Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Prostamax dosing — protocols, safety, and where to buy.
Dose Range
10 mg oral capsule, 1-2 daily for 10-30 days
Dosage Calculator
Calculate exact dosing for Prostamax.
Dosing Protocols
Beginner Prostamax Protocol (first prostate-focused cycle)
- Baseline workup: PSA if not done in past 12 months (age and risk appropriate). IPSS score documented. Post-void residual if symptomatic urinary retention. Urinalysis. Urologist evaluation if moderate-severe symptoms, blood in urine, recurrent UTI, or any red-flag features.
- Product form: 20 mg oral capsule from vendor with third-party HPLC. Alternatively, rectal suppository form (Vitaprost-style) if using the extract-parent product rather than synthetic Prostamax.
- Dose: 1 capsule (20 mg) once daily, sublingual or oral on empty stomach 30–45 min before breakfast.
- Duration: 10 consecutive days.
- Washout: 60 days before repeat cycle.
- Monitoring: Daily IPSS-style symptom tracking during cycle and for 4 weeks post-cycle. Track urinary frequency, urgency, nocturia, flow strength, post-void satisfaction.
- Continue existing prostate therapy. Do not stop alpha-blockers, 5-ARI, or other urological medications to test Prostamax alone.
- Stop criteria: Acute urinary retention, haematuria, fever with urinary symptoms (possible prostatitis), severe worsening of symptoms, rash, unexpected side effect.
- Setting expectations: Mild subjective effects at best. Do not expect prostate volume reduction or dramatic LUTS improvement from a 10-day peptide cycle. Evidence-graded BPH pharmacotherapy takes weeks to months for full effect; Prostamax is unlikely to exceed this.
Intermediate Prostamax Protocol (experienced bioregulator user)
- Product form: 20 mg oral capsule or lyophilised synthetic KEDP peptide (requires reconstitution) or Prostatilen-style rectal suppository.
- Dose: 20 mg oral daily OR 2–5 mg SC daily OR 1 suppository daily per product label.
- Duration: 10 consecutive days per cycle.
- Cycling: Twice yearly typical.
- Rotation: Pair with Testagen in alternating cycles for broader male-reproductive support.
- Monitoring: Annual PSA (age-appropriate), annual IPSS documentation, urinary flow studies if indicated, post-void residual if symptomatic.
- Stack integration: Continue evidence-graded BPH therapy. Prostamax is experimental layer.
- Expectations: Modest symptom improvement over multiple cycles in some users. Structural prostate changes unlikely.
- Cost honesty: Annual Prostamax cycling 150–400 USD. Compare to prescription BPH therapy (tamsulosin generic is pennies per day, finasteride likewise) which is dramatically more cost-effective per unit symptom improvement.
Advanced Prostamax Protocol (Khavinson male-reproductive rotation)
For experienced Khavinson users with established baseline prostate monitoring.
- Annual rotation:
- Monitoring: Baseline and annual PSA, annual DRE (age appropriate), IPSS quarterly, urinary flow testing annually if symptomatic.
- Stack on evidence-graded base: Alpha-blocker, 5-ARI, PDE5 inhibitor, or appropriate combination per urology. Saw palmetto, Pygeum, beta-sitosterol as supplement layer. Bioregulator on top.
- Urology coordination. Annual urology visit with full disclosure of supplement and peptide use.
- Stop and reassess if rising PSA, new symptoms, haematuria, or retention. Rule out prostate cancer with appropriate workup.
- Realistic expectation: Does not substitute for evidence-graded BPH pharmacotherapy. May add modest symptomatic benefit as part of a comprehensive approach.
Commonly Stacked With
Stacking Notes
Khavinson rotation
Prostamax cycles alongside Testagen (complementary male reproductive), Epitalon, Pinealon, Thymogen, Vilon, Livagen, Bronchogen, Cardiogen, Cartalax, Chonluten, and Ovagen.
Male prostate-focused rotation:
- Days 1–10: Prostamax 20 mg oral/sublingual daily
- Days 11–70: Washout
- Days 71–80: Testagen 20 mg daily
- Days 81–140: Washout
- Days 141–150: Epitalon 5–10 mg SC daily
- Days 151–210: Washout
- Days 211–220: Prostamax repeat cycle
Evidence-graded BPH stack (preferred)
- Appropriate urological workup — IPSS, PSA (age-appropriate), physical, urinalysis.
- Lifestyle — fluid, caffeine, alcohol, weight.
- Alpha-blockers — tamsulosin 0.4 mg, alfuzosin 10 mg, silodosin 8 mg.
- 5-alpha reductase inhibitors — finasteride 5 mg, dutasteride 0.5 mg for larger prostate.
- PDE5 inhibitors — tadalafil 5 mg daily for LUTS/ED overlap.
- Saw palmetto 320 mg standardised daily — modest evidence.
- Pygeum africanum 100–200 mg daily — modest evidence.
- Beta-sitosterol 60–130 mg daily.
- Minimally invasive or surgical procedures for treatment-refractory disease.
- Experimental bioregulators (Prostamax, Prostatilen) as tier-10.
Stacking with alpha-blockers
No documented interactions. Continue alpha-blocker therapy during Prostamax cycles. Do not substitute.
Stacking with 5-ARI
No documented interactions. Continue finasteride or dutasteride. Prostamax does not provide 5-alpha reductase inhibition.
Stacking with PDE5 inhibitors
Continue prescribed PDE5 inhibitor (tadalafil 5 mg daily for LUTS/ED). No documented Prostamax interaction.
Stacking with testosterone replacement therapy (TRT)
If on TRT, continue it. No documented Prostamax interaction. The prostate monitoring requirements of TRT (PSA, DRE annually) are unchanged by adding Prostamax.
Stacking with supplements
Common combinations in male-health community: Prostamax + saw palmetto + Pygeum + beta-sitosterol + zinc 15–30 mg daily + selenium 100 mcg daily. No documented interactions. Synergy is theoretical.
Stacking with other peptides
- Prostamax + BPC-157 — BPC-157's tissue regeneration mechanism pairs naturally with Prostamax's prostatic framework.
- Prostamax + Testagen — male reproductive bioregulator pair in Khavinson framework.
- Prostamax + Epitalon — general anti-aging combination.
Contraindicated combinations
Do not substitute for appropriate BPH pharmacotherapy. Do not substitute for antibiotic therapy in bacterial prostatitis. Do not use during active prostate cancer workup or treatment without oncology approval.
Side Effects & Safety
Contraindications
## Contraindications ### Absolute contraindications - **Active prostate cancer or recent history** - **Elevated PSA under investigation** — complete workup first - **Unexplained haematuria** — evaluate before use - **Acute urinary retention** — medical emergency - **Active bacterial prostatitis or UTI** — antibiotic therapy required - **Paediatric and adolescent use** — not applicable - **Known hypersensitivity** to Prostamax or any Khavinson bioregulator - **For extract/suppository form: bovine/porcine protein allergy** ### Relative contraindications (supervised use only) - **Severe BPH with complications** (recurrent UTI, bladder stones, hydronephrosis) - **Recent prostate surgery** (within 6 weeks) - **Post-prostatectomy with PSA surveillance** — coordinate with urology - **Rectal/anal disease** — for suppository form - **Severe renal or hepatic impairment** - **Active radiation therapy to prostate** ### Use with caution - **Multiple BPH medications** — alpha-blocker + 5-ARI + anticholinergic polypharmacy - **TRT with ongoing PSA monitoring** — maintain PSA surveillance - **Age 80+ with polypharmacy** - **Coagulopathy** — for suppository form (rectal bleeding risk) ### Quality-of-supply contraindication Require third-party HPLC testing. For suppository form, pharmaceutical-grade manufacturing required. ### Symptoms requiring evaluation, not bioregulators Blood in urine, dysuria with fever, acute urinary retention, rising PSA, new haematospermia, weight loss with urinary symptoms, bone pain — urological evaluation required, not Prostamax self-treatment.
Additional Notes
Dosage Notes
Oral/sublingual dosing
- 1 capsule (20 mg nominal) once daily
- Sublingual ~60 seconds
- Empty stomach 30–45 min before first meal
- Duration 10 days per cycle
- Washout 60–90 days
Subcutaneous dosing
- 2–5 mg SC once daily
- 10 days per cycle
- 60-day washout
Rectal suppository (Prostatilen-style extract)
Vitaprost / Prostatilen suppositories are the Russian-pharmaceutical form of the parent polypeptide extract. Typical dosing per manufacturer label:
- 50 mg suppository rectally, 1–2 times daily
- 10–14 day courses
- Repeat every 3–6 months as needed
The suppository form is not directly equivalent to synthetic Prostamax oral dosing but occupies the same therapeutic niche.
Cycling rationale
10-on / 60-off is Khavinson convention. Parent extract typically uses 10–14 day suppository courses.
Maximum dose
Do not exceed 20 mg oral or 5 mg SC daily. Do not exceed manufacturer suppository label for extract form.
Continuous dosing
Do not run continuous cycles.
Age considerations
Russian studies enrol men aged 50+ with BPH or chronic prostatitis. No paediatric use. No adolescent use.
Timing relative to PSA testing
PSA is sensitive to prostatic manipulation. Do not use rectal suppository form within 48 hours of PSA blood draw as it could theoretically elevate PSA values. Oral/SC routes do not affect PSA timing.
Renal and hepatic impairment
No formal dose adjustment. Avoid in severe impairment.
Frequently Asked Questions
What is the recommended Prostamax dosage?
The typical dose range for Prostamax is 10 mg oral capsule, 1-2 daily for 10-30 days. Always start with the lowest effective dose.
How often should I take Prostamax?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Prostamax need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Prostamax side effects?
## Side Effects and Safety Prostamax short-term safety signal from Russian literature is mild. Long-term pharmacovigilance is absent. ### Reported short-term adverse effects - **Gastrointestinal:** mild nausea, dyspepsia (oral form). Self-limited. - **Local irritation** (suppository form): mild rectal irritation, occasional minor discomfort. - **Headache:** occasional mild headache. - **Rare allergic reactions:** occasional mild rash. - **No serious adverse urological events** attributable to Prostamax in published literature at convention dosing. ### Theoretical concerns - **Prostate cancer risk.** BPH and prostate cancer are distinct diseases but occur in the same population. Chromatin-modulating peptides theoretically could affect cancer pathways if malignant cells are present. Active prostate cancer or elevated PSA under investigation is a contraindication. - **Drug interactions.** No formal studies. Theoretical interactions with alpha-blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, or other BPH/prostatitis medications have not been characterised. - **Hormonal interactions.** Theoretical effects on androgen signalling. No empirical testing. ### Pregnancy and breastfeeding Not relevant — Prostamax is used in males. However, handling by pregnant partners (e.g., during pill preparation or suppository administration) should follow standard peptide precautions; finasteride has pregnancy category X contraindication for touch-handling by pregnant women, but Prostamax has no specific data on this. ### Paediatric use Not indicated. No paediatric safety data. ### Active prostate cancer Do not use Prostamax in active prostate cancer or recent history. Theoretical chromatin-modulating mechanism is not safe in proliferative disease of target organ. ### Elevated PSA under investigation If PSA is elevated and being worked up (new elevation, rising trend, abnormal DRE), complete the workup before considering Prostamax. Do not use to "treat" elevated PSA without diagnosis. ### Active urinary tract infection or bacterial prostatitis Appropriate antibiotic therapy is required. Prostamax is not a substitute. ### Acute urinary retention Medical emergency — catheterise and evaluate. Do not attempt to treat with bioregulators. ### Severe BPH with complications Patients with recurrent UTI, bladder stones, hydronephrosis, renal insufficiency from obstruction, or acute-on-chronic urinary retention require urological management, not bioregulator self-treatment. ### Post-prostatectomy Do not use Prostamax in the immediate post-prostatectomy period without urological approval. Wound healing and PSA surveillance dominate the recovery context. ### Supply quality Require third-party HPLC confirmation. For suppository form, confirm sterility and pharmaceutical-grade manufacturing. ### Overall assessment Short-term signal mild. Long-term absent. Particularly concerning in prostate cancer context and with elevated PSA workup. Treat as experimental with specific contraindications strictly enforced.
Where can I buy Prostamax?
Visit our vendor directory to find trusted sources for Prostamax.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.